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We report derivatives of gallium(III) tris(pentafluorophenyl)cor-
role, 1 [Ga(tpfc)], with either sulfonic (2) or carboxylic acids (3, 4) as
macrocyclic ring substituents: the aminocaproate derivative, 3
[Ga(ACtpfc)], demonstrated high cytotoxic activity against all
NCI60 cell lines derived from nine tumor types and confirmed very
high toxicity against melanoma cells, specifically the LOX IMVI and
SK-MEL-28 cell lines. The toxicities of 1, 2, 3, and 4 [Ga(3-ctpfc)]
toward prostate (DU-145), melanoma (SK-MEL-28), breast (MDA-
MB-231), and ovarian (OVCAR-3) cancer cells revealed a dependence
on the ring substituent: IC50 values ranged from 4.8 to >200 μM;
and they correlated with the rates of uptake, extent of intracel-
lular accumulation, and lipophilicity. Carboxylated corroles 3 and
4, which exhibited about 10-fold lower IC50 values (<20 μM) rel-
ative to previous analogs against all four cancer cell lines, dis-
played high efficacy (Emax = 0). Confocal fluorescence imaging
revealed facile uptake of functionalized gallium corroles by all
human cancer cells that followed the order: 4 >> 3 > 2 >> 1
(intracellular accumulation of gallium corroles was fastest in mel-
anoma cells). We conclude that carboxylated gallium corroles are
promising chemotherapeutics with the advantage that they also
can be used for tumor imaging.
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Corroles are macrocyclic molecules (1) related to porphyrins(2–4) and other aromatic macrocycles whose pharmacologi-
cal properties have led to the development of many drugs (5, 6).
Challenges that must be addressed to realize the full potential of
these drugs, however, include synthesis of analogs, determination
of pharmacokinetics, targeting, and bioavailability (6, 7). We
have taken up the challenge of functionalizing metallocorroles to
enhance cell permeability (8, 9). We hope to achieve this goal
while still retaining the inherent therapeutic properties of these
macrocyclic compounds.
Corroles have received a great deal of attention in recent years
(10–13), owing to dramatic advances in methods for their prep-
aration (14–31). Of interest here is a gallium(III) complex, 1
[Ga(tpfc)] (32–35), where tpfc represents the trianion of 5,10,15-
tris(pentafluorophenyl)corrole [H3(tpfc)]. 1 is highly fluorescent,
with an emission quantum yield far exceeding that of its zinc
porphyrin analog (36–38). The macrocyclic ring of this complex
can be selectively modified to afford molecules that exhibit a
wide range of physical and chemical properties (1). Previous work
focused on a sulfonic acid derivative of Ga(tpfc), 2 [Ga(2,17-
S2tpfc)]; notably, 2 possessed potent antitumor activity both in
vitro (using human cancer cells) and in vivo (using murine model
animals), making it a powerful reagent for both imaging and
therapeutic targeting of cancer cells (39, 40). Additional studies on
the mechanism of cytotoxicity demonstrated that numerous cancer
cell lines rapidly take up 2 in vitro and induce cell cycle arrest at
late M phase (41, 42). Replacement of bis-sulfonic acids with para-
pyridinium substituents (5) was shown to improve uptake and
activity, whereas ortho-pyridinium substitution (6) completely ab-
lated toxicity, indicating that functional group modifications of the
corrole can have profound effects on biological activity (41).
To examine the effect of functional group substitution on the
cell permeability and cytotoxic activity of corroles, we have ex-
panded our earlier work on 1; specifically, we have introduced
various substituents and examined cellular uptake and anticancer
activity of several derivatives. Compound 1 is treated with sul-
fonic acid to generate 2, with aminocaproic acid to generate
carboxylic acid 3, or with phosgene to generate 4. We report that
enhanced corrole potencies and intracellular uptakes are de-
pendent upon functional group substitution, and that selectively
functionalized corroles can augment anticancer activity by al-
tering cell membrane permeability.
Results and Discussion
Synthesis of Gallium Corroles. 1 (32), 2 (33), and 4 (34) were obtained
via literature methods, and molecular masses were confirmed by
MALDI-TOF mass spectrometry (Fig. 1). The aminocaproate-
substituted corrole 3 was synthesized in 37% yield by nucleophilic
aromatic substitution of a para-fluoro substituent on the penta-
fluorophenyl ring of 1 with a substoichiometric amount of 6-ami-
nocaproic acid in anhydrous dimethyl sulfoxide (DMSO) with 1%
anhydrous pyridine at 100 °C (Scheme 1). This synthesis followed
procedures that have been used to prepare amine-substituted cor-
roles (43). These reactions are highly selective in that only the para-
fluoro substituent undergoes substitution.
Although preparation of 4 requires phosgene and can only
be performed on the metallated corrole (34), 3 can be syn-
thesized using either metallated or free base corrole and does
not require harsh reagents. Compound 3 is a promising candi-
date for both imaging applications and potential development as
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a chemotherapeutic, as it is easily solubilized in water, and easily
prepared and purified.
Modulation of Cytotoxicity by Substituents on the Corrole Ring. The
effects of bis-sulfonate, carboxylate, and aminocaproate ring
substituents on gallium corrole cytotoxicities were examined
using four human cancer cell lines, representing tumors of dif-
ferent origin selected (44) based on previously described sensi-
tivities (41). Each cell line, DU-145 (prostate), SK-MEL-28
(melanoma), MDA-MB-231 (breast), or OVCAR-3 (ovarian),
was incubated in growth medium with varying concentrations of
1–4 at 37 °C for 72 h in the dark, and the cytotoxicity as a
function of concentration was measured using the MTS assay.
Dose–response curves are shown in Fig. 2.
Fig. 1. Structures of functional group-substituted derivatives of corroles. For clarity, the axial pyridine is not shown in the structures.
Scheme 1. Synthetic scheme for 3 [Ga(ACtpfc)]. Reagents and conditions: 6-aminocaproic acid, K2CO3, DMSO, 1% pyridine, 100 °C, 18 h.
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IC50 values ranged from 4.8 to 17.6 μM with carboxylated
corroles 3 and 4; these corroles had the highest anticancer ac-
tivities against all cell lines (Fig. 2 and Table 1). In particular, 4
displayed promising activity against the SK-MEL-28 melanoma
line, with an IC50 value of 4.8 μM. The cytotoxicities of the
carboxylated corroles toward all cell lines were nearly identical,
except for 4 in SK-MEL-28 cells, with IC50 values in the range of
10–20 μM (Fig. 2 and Table 1), or about 10-fold lower against the
same cell lines relative to 1 and 2. With the exception of the
activity of 1 against SK-MEL-28 and OVCAR-3 cell lines, with
IC50 values of 61.3 and 58.1 μM, respectively (Table 1), the IC50
values of 1 and 2 had values ranging from 100 to 274 μM. The
order of magnitude improvement in IC50 against SK-MEL-28
results from substitution with a single carboxylic acid at the 3
position of 1, lowering the IC50 of 4 to 4.8 μM (Fig. 1 and Table
1). Against the prostate cancer cell line DU-145, bis-sulfonated 2
displayed an IC50 of 159 μM, whereas the carboxylated analog 4
was ∼12-fold lower (12.9 μM). In general, the bis-sulfonated
corroles were the least effective against all tested cell lines, with
the lowest observed IC50 values (∼130 μM) against the mela-
noma line SK-MEL-28 and breast cancer cell line MDA-MB-
231. This finding contrasts with that for monocarboxylated 3 and
4 corroles, which displayed IC50 values of <20 μM against all cell
lines tested, with markedly good activities against SK-MEL-28
and OVCAR-3 lines. The mean IC50 values for all carboxylated
corroles (12.8 ± 1.3 μM) revealed twofold to threefold higher
potency than that reported for cisplatin [46.4 ± 12.4 μM (45) and
39 μM (46)] in MDA-MB-231 cells. Although the IC50 values are
similar for the carboxylated Ga(III) corroles, data in Table 1
suggest that 4 possesses somewhat greater potency relative to
aminocaproate analog 3.
Although the IC50 value is typically the principal metric for the
effectiveness of a potential drug, other parameters involving the
slope of the dose–response curve (Hill slope, ׀γ׀) and the maxi-
mum effect (Emax), which represent the compound’s range of
useful concentrations and efficacy, respectively, also should be
considered in evaluating drug response (47, 48). For example, a
drug with low efficacy may only kill 20% of cells even at the
highest doses (Emax = 0.8), or a drug could have a shallow dose–
response curve (׀γ׀ < 1), meaning that the therapeutic benefit or
cytotoxic effect may not increase substantially as the maximum
tolerated dose is approached. The effectiveness of 1–4 was fur-
ther evaluated by these additional parameters; and the data
revealed considerably steep slopes (׀γ׀ ≥ 1.0) for all derivatives in
all cell lines tested, with values ranging from 0.9 to 9.7 (Fig. 2 and
Table 1). The steep slopes of the dose–response curves were
indicative of homogeneous cell populations with highly uniform
drug responses (47). The mean slopes for carboxylated corroles
Fig. 2. Cytotoxic effects of functionalized gallium(III) corroles on human cancer cells. Dose–response curves for a 72-h exposure of human tumor cell lines,
prostate (DU-145), melanoma (SK-MEL-28), breast (MDA-MB-231), and ovarian (OVCAR-3) to (A) 1, (B) 2, (C) 3, or (D) 4 were evaluated using the MTS assay.
The viability of each corrole-treated cell line is expressed as a percentage of untreated control growth. A sigmoidal dose–response curve was fitted to the data
using GraphPad Prism 6. Data represent the mean ± SD of three independent experiments.
E2260 | www.pnas.org/cgi/doi/10.1073/pnas.1517402113 Pribisko et al.
3 and 4 (4.2 ± 0.9) were about twofold steeper than those for 1
(2.5 ± 1.1) and 2 (2.2 ± 0.5), suggesting that the cytotoxic effects
or therapeutic benefit of the carboxylated derivatives will increase
substantially as the maximum tolerated dose is approached.
The quantifying maximal effect parameter (Emax) revealed
high compound efficacy for 1–4, except for 1 in MDA-MB-231
cells (Fig. 2). In general, Emax is defined between 1 at low doses
and 0 at high doses, which corresponds to 100% cytotoxicity (48).
With the exception of 1 in MDA-MB-231 cells (Emax = 0.25), the
maximum cytotoxic effect for all compounds tested was ≤0.02,
indicating high efficacy (Fig. 2). The lower efficacy of 1 in MDA-
MB-231 cells may be explained in part by the “fraction kill”
theory, which proposes that inhibitors of cell cycle progression,
such as paclitaxel and docetaxel, kill only the subset of cells that
pass through S or M phases in the presence of the drug (49, 50).
Therefore, cells with substantially longer doubling times, and
thus smaller mitotic and S-phase fractions, would have higher
values for Emax (48). Because gallium corroles were previously
shown to arrest cells at the late M phase (41) and the doubling
time of MDA-MB-231 cells [population doubling time (PDT),
41.9 h] is considerably longer than DU-145 (PDT, 32.3 h),
SK-MEL-28 (PDT, 35.1 h), and OVCAR-3 (PDT, 34.7 h) cells,
the reduced mitotic or S-phase fractions of MDA-MB-231 cells
that are susceptible to drug-induced toxic effect could account
for the lower efficacy (Emax = 0.25) observed for 1 in MDA-
MB-231 cells (Fig. 2). Although correlation of Emax with cell
proliferation rate has often been shown for cell cycle inhibitors
(48), the fraction kill theory does not always apply. For in-
stance, Oxamflatin and NSC663284, which arrest cells at both
G1 and G2/M, exhibit high efficacy (Emax = 0) in all 64 breast
cancer cell lines tested with varying cell proliferation rates. In
summary, 1 and its derivatives, with the exception of 1 in MDA-
MB-231 cells, were effective in killing 100% of cancer cells at
the highest doses.
Uptake of Ga(tpfc) Derivatives. The intense fluorescence of gallium
corroles was exploited to examine intracellular accumulation
using confocal microscopy and ImageXpressultra analysis to
measure the rate of uptake of differentially substituted deriv-
atives across all cell lines. Avidity of cellular uptake can influ-
ence the observed cytotoxicity of corroles, as we have previously
described (41). Confocal image analysis was performed on DU-
145 (prostate), SK-MEL-28 (melanoma), MDA-MB-231 (breast),
or OVCAR-3 (ovarian) cells incubated with 3 μM 1, 2, 3, or 4 in
complete or unsupplemented media for 3 h in the dark; repre-
sentative images are shown for DU-145 cells (Fig. 3). The nuclei
and plasma membranes of cells were visualized by labeling with
DAPI (blue fluorescence) and wheat germ agglutinin (WGA)–
Alexa Fluor 488 conjugate (green fluorescence), which bind to
nuclear DNA and N-acetylglucosamine, respectively. Gallium
corroles were readily observable in situ as red fluorescence of
varying intensities in cells treated with 2, 3, and 4; in contrast, red
fluorescence was absent in untreated cells (Fig. 3). In cells
treated with 3 μM 1 for 3 h, red fluorescence was not apparent
(data not shown), whereas analysis of cellular uptake kinetics
revealed that less than 5% of cells were able to internalize 1 at
this time point (Fig. 4A). The intensities of red fluorescence were
much greater in cells exposed to 2 and 4 compared with 3, even
though the IC50 of 3 is about the same as 4 and 10-fold lower
than 2 (Fig. 3 and Table 1). The standard curves of corrole
fluorescence versus compound concentration generated for 1
and its derivatives differed significantly, most likely owing to
differences in quantum yields, absorption cross-sections, and
solubilities (data not shown); these data confirmed that fluo-
rescence intensity measurements cannot be used to predict or
directly compare the intracellular concentrations of different
gallium corroles. However, the relative intracellular concentra-
tions of a single compound can be assessed by its fluorescence
intensity and compared among different cell lines. Data obtained
from confocal image analysis verified that intracellular uptake of
1–4 can be monitored by fluorescence microscopy for all cell
lines tested.
To quantify the kinetics of intracellular uptake and accumula-
tion of each 1 derivative, ImageXpressultra, a laser point-scanning
confocal microscope, was used for analyses. Cellular uptake of
1–4 was assessed in human cancer cell lines DU-145 (prostate),
SK-MEL-28 (melanoma), MDA-MB-231 (breast), or OVCAR-3
(ovarian) at a final concentration of 30 μM. Cells were incubated
at 37 °C in the dark for 0.25, 1, 3, or 24 h. Results are presented
in Fig. 4 A–D for 1, 2, 3, and 4, respectively. Each graph indicates
the percentage of cells with observable red/corrole fluorescence
(y axis) versus incubation time (x axis) and the median relative
fluorescence intensity (RFU), which is directly proportional to
the amount of intracellular accumulation (z axis). Functional
group substitution of 1 resulted in significant differences in the
rate of uptake, as follows: 4 >> 3 > 2 >>1 (Fig. 4 A–D). Within
15 min, 4 fluorescence was observable in ∼80% of ovarian cancer
cells, 97% of breast cancer cells, and >99% of prostate cancer and
melanoma cells (Fig. 4D), whereas up to 3 and 24 h were required
to label >80% of cells from all four cancer lines with 3 and 2,
respectively (Fig. 4 B and C). For 1, significant uptake (≥80%
cells) in melanoma, ovarian, and breast cancer cell lines required
24 h. The uptake of 1 was quite slow in prostate cancer cells, as
<5% of cells displayed red fluorescence after 3 h and only about
50% of cells were positive for corrole after incubation for 24 h
(Fig. 4A). In the case of 4 in DU-145, SK-MEL-28, and OVCAR-3
cells (Fig. 4D), as well as 3 in OVCAR-3 cells (Fig. 4C), the
proportion of corrole-positive cells decreased from nearly 100% at
3 h to about 30–75% at 24 h. Less than 30% of the average
numbers of cells analyzed for each cell line was available for
the analysis of corrole uptake in these cases; these decreases
could result from the cytotoxicity of 3 and 4 following 24 h of
incubation. As a result, analysis of uptake among the surviv-
ing subpopulation revealed an ostensibly lower proportion of
corrole-positive cells.
Intracellular accumulation, which correlates with the median
RFU, was compared among the four human cancer cell lines
and revealed the most efficient uptake of 1–4 into melanoma
(SK-MEL-28) cells (Fig. 4 A–D). After 3 h of incubation, the
Table 1. Dose–response parameters for gallium corroles
Compound Cells*
IC50
† Slope (γ)‡
IC50 ±SE γ ±SE
1 DU-145 134.6 10.9 −2.1 0.3
SK-MEL-28 61.3 9.9 −0.9 0.1
MDA-MB-231 100.8 6.8 −5.7 3.9
OVCAR-3 58.1 7.2 −1.1 0.2
2 DU-145 158.9 16.2 −1.6 0.3
SK-MEL-28 131.4 18.5 −2.0 0.5
MDA-MB-231 129.2 13.2 −1.3 0.2
OVCAR-3 274.2 15.5 −3.7 0.9
3 DU-145 17.6 0.8 −5.3 1.1
SK-MEL-28 14.4 0.7 −4.2 0.5
MDA-MB-231 13.7 1.0 −2.7 0.4
OVCAR-3 12.7 0.6 −2.5 0.2
4 DU-145 12.9 0.5 −3.9 0.4
SK-MEL-28 4.8 0.3 −1.4 0.1
MDA-MB-231 15.3 2.0 −9.7 4.8
OVCAR-3 11.1 0.4 −3.5 0.4
*Human cancer cells were exposed to each compound for 72 h. Data repre-
sent the mean of three independent experiments.
†IC50 values are reported in micromolar concentration.
‡Hill slopes (γ) are unitless.
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fluorescence of 4 was approximately twofold to threefold higher in
melanoma cells compared with prostate, breast, and ovarian cancer
cells (Fig. 4D). A twofold enhancement of fluorescence in mela-
noma cells compared with the other three cell lines was observed
for 1, 2, and 3 after 24 h (Fig. 4 A–C). The most efficient uptake of
gallium corroles into melanoma (SK-MEL-28) cells has been
proposed to be consistent with transferrin-mediated transport (41),
because these cells are well known to avidly accumulate iron via
this mechanism (51, 52). The exceptional efficiency of gallium
corrole uptake and intracellular accumulation in melanoma cells
correlates with an observable increase in cytotoxic activity against
these cells over other cell lines for 1 and 4 (Figs. 2 and 4 and
Table 1); but for 2 and 3, the cytotoxic activity is similar among all
cell lines and does not correlate with the accumulated corrole
levels (Figs. 2 and 4 and Table 1). Overall, excellent kinetics of
intracellular uptake and accumulation, especially in melanoma
cells, were found for 3 and 4, suggesting that substitution with
carboxylic acid or aminocaproic acid increases cell permeability.
The mechanisms of uptake of gallium corroles, and macrocy-
clic compounds in general, into cancer cells remain elusive, and
factors that control cell permeability are mostly unknown (5, 7).
Recent research in drug discovery and development (7) has
focused on altering the physical and chemical properties of
macrocycles in attempts to improve cell permeability (5, 53).
Some chemical properties that have been shown to enhance cell
permeability and uptake include lower molecular weight (Mr),
smaller polar surface area (tPSA), and higher calculated
lipophilicity (cLogP) (5). Predictions of tPSA and cLogP were
made for substituted derivatives 2, 3, and 4, using ChemDraw
(Table 2). The carboxylated corroles, 3 and 4, with enhanced
cellular uptake, cell permeability, and potency relative to bis-
sulfonated 2, showed lower Mr, smaller tPSA, and increased
cLogP (Table 2).
Profile of 3 [Ga(ACtpfc)] Sensitivity in a NCI60 Cell Panel. In view of
the promising results observed for carboxylated corroles, 3 was
selected for expanded cell screening to uncover additional sus-
ceptible cancer cell lines. The cytotoxic activity of 3 was tested at
a dose of 10−5 M against 60 human cancer cell lines representing
nine distinct tumor types in the anticancer screening program
of the National Cancer Institute (NCI). The in vitro parameters
for cytotoxicity, growth percent, and lethality were obtained
for 3 and reported as a mean graph of the percent growth of
treated cells (Fig. 5). Bars in the mean graph depict the de-
viation of individual tumor cell lines from the overall mean
value for all cells tested. Bars that project to the right of the
mean represent cell lines that are more sensitive to 3, whereas
cell lines less sensitive to the compound display bars that project
to the left.
The numerical values associated with this assay represent
growth relative to the no-drug control and the numbers of cells at
time 0 (Fig. 5). This allows detection of both growth inhibition
Fig. 3. Intracellular uptake of functional group-substituted derivatives of 1 [Ga(tpfc)]. Prostate cancer cells (DU-145) were treated with 3 μM 2, 3, 4 for 3 h or
untreated (medium only). Cells were labeled with WGA conjugated to Alexa Fluor 488 and DAPI. Images were obtained at 40×magnification using an upright
confocal microscope and displayed in three-color channels with a merged image. Fluorescence settings were kept constant between imaging, and images
were captured at fixed exposure and gain settings. (Scale bar: 20 μm.)
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(values between 0 and 100) and lethality (values less than 0). For
example, a value of 100 signifies no growth inhibition, 40 means
60% growth inhibition, 0 means no net growth over the course of
the experiment, −40 means 40% lethality, and −100 indicates all
cells are dead. The percentage of growth inhibition and lethality
resulting from 3 is given in Table 3. In most cell lines, inhibition
of cell proliferation was observed ranging from 30% to 99%
following exposure to 10 μM 3 for 48 h, with an average growth
inhibition of 70%. Growth inhibitions reflect cytostatic activity of
the compound as previously shown for 2 (41). In contrast, cell
lethality is only evident in melanoma cells, specifically the LOX
IMVI and SK-MEL-28 cell lines. Overall, 3 is highly active
against all NCI60 cell lines derived from nine tumor types (Table
3), suggesting that carboxylated gallium corroles are effective,
cell-permeable chemotherapeutic agents.
Conclusions
Gallium corroles with different ring substituents exhibited vari-
able uptake rates and cytotoxic activity against numerous human
cancer cell lines. The uptake, intracellular accumulation, and
potency (IC50) varied by compound: carboxylated derivatives 3
and 4 augmented cell permeability, as revealed by enhanced
uptake rates, and increased intracellular accumulation, resulting
in higher potency compared with 1 and 2. The carboxylated
corroles exhibited strong cytotoxic effects in prostate, melanoma,
breast, and ovarian cancer cells; the effective cytotoxic dose
(<20 μM) was lower than that of a widely used chemotherapeutic
agent, cisplatin (45, 46), as well as those of other gallium com-
pounds under study as therapeutic agents (54–56). Compound 4
was exceptionally active as a cytotoxic agent against melanoma
SK-MEL-28 cells (IC50 = 4.8 μM); notably, >99% of cells
exhibited intracellular corrole accumulation within 15 min. In
comparison with 2, derivatives 3 and 4 have lower molecular
Fig. 4. Kinetics of intracellular uptake and accumulation of 1 and its derivatives by DU-145 (black), SK-MEL-28 (red), OVCAR-3 (blue), and MDA-MB-231
(green) cancer cells were determined using the ImageXpressultra system. Cells were treated with 30 μM (A) 1 [Ga(tpfc)], (B) 2 [Ga(2,17-S2tpfc)], (C ) 3
[Ga(ACtpfc)], or (D) 4 [Ga(3-ctpfc)] for the amount of time indicated on the x axis. The y axis represents a percentage of corrole-positive cells with
observable intracellular red fluorescence. The extent of corrole uptake and intracellular accumulation was directly proportional to the median
fluorescence intensity (RFU) on the z axis. Cell images were obtained at 20× magnification using filters for blue (DAPI) and red fluorescence.
Table 2. Chemical properties of functional group substituted
1 [Ga(tpfc)]
Compounds Mr
* tPSA† cLogP‡
2 1,021.30 135.9 9.6
3 974.37 62.0 13.5
4 907.21 58.8 13.1
ChemBioDraw Ultra (version 13.0.2.3021).
*Molecular weight.
†Calculation of polar surface area based on fragment contributions.
‡Calculated logP based on Biobyte algorithm.
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weights (Mr), smaller polar surface areas (tPSA), and higher
calculated lipophilicities (cLogP), all chemical properties asso-
ciated with enhanced cell permeability and uptake (5). The
carboxylated corroles also displayed high efficacy in cell killing
and a highly homogeneous cytotoxic response within each cell
population.
Because the synthesis of 3, which has anticancer activity close
to that of 4, does not require the use of harsh reagents, it rep-
resents an easily and safely prepared anticancer lead that also
can function as a fluorescence imaging agent.
Materials and Methods
Materials. 1, 2, and 4 were prepared by literature methods (Fig. 1) (32–34).
The synthesis and characterization of compound 3 (Scheme 1) proceeded as
follows: a round-bottom flask was charged with 1 (20.0 mg, 0.025 mmol),
6-aminocaproic acid (3.1 mg, 0.024 mmol), and K2CO3 (18.0 mg, 0.13 mmol)
under argon. To this mixture was added anhydrous DMSO (0.5 mL) and
anhydrous pyridine (1%). The reaction mixture was heated to 100 °C
and stirred for 18 h, after which it was cooled and then diluted with CHCl3
(10 mL), washed sequentially with H2O (4 × 10 mL) and brine (1 × 10 mL),
and then dried over Na2SO4. The solvent was removed in vacuo, and the
crude residue was purified by flash chromatography [SiO2, 1% pyridine,
0–10% (vol/vol) MeOH in CH2Cl2] to provide 9.1 mg (37%) of mono-
carboxylate as a purple solid. Characterization of 3 was performed using
1H/19F NMR spectroscopy and MALDI-TOF mass spectrometry, although these
techniques did not distinguish between regioisomers with monosubstitution
at the 5-, 10-, or 15-fluoro position. 1H NMR (300 MHz, CDCl3) δ 9.11–9.03
(m, 2H), 8.88–8.63 (m, 2H), 8.58–8.53 (m, 4H), 3.69–3.64 (m, 2H), 2.49–2.45
(t, J = 6.2 Hz, 2H), 1.87–1.75 (m, 2H), 1.67–1.55 (m, 2H), 0.91–0.85 (m, 2H);
19F NMR (282 MHz, CDCl3) δ −137.17, −137.23, −137.69, −137.72, −140.11,
−141.69, −152.66, −152.97, −153.14, −160.54, −160.60, −161.63, −162.03,
−162.91. MALDI-TOFm/z calculated for C43H20F14GaN5O2 [M+H]+: 974.065,
found: 974.126. UV-Vis (DMSO): λmax (e) 420 nm (130,300 M−1·cm−1).
The gallium corroles were solubilized in DMSO, and concentrations were
determined by UV-Vis using calculated extinction coefficients: (1) e420nm =
284,000 cm−1·M−1, (2) e424nm = 74,700 cm
−1·M−1, (3) e420nm = 130,300 cm
−1·M−1,
(4) e426nm = 130,000 cm
−1·M−1 (Fig. 1). Stock solutions were stored in the dark at
room temperature before use.
Fig. 5. Mean graph representation of growth inhibition effects of 3 [Ga(ACtpfc)]. Carboxylated gallium corrole submitted to the NCI screen were evaluated
against 60 human tumor cell lines. Growth percent and lethality were obtained at a single dose (10−5 M) of 3 and the mean growth percent across all 60 cell
lines was calculated. The individual response of each cell line to the compound is depicted by a bar graph extending either to the right or left of the mean.
Bars projecting to the right represent cell lines that are more sensitive than average, whereas less sensitive cell lines show bars projecting to the left. The
length of each bar is proportional to the relative sensitivity compared with the mean determination. The graph was color-coded by tissue of origin: red,
leukemia cell line; blue, lung cancer; green, colon cancer; gray, CNS cancer; coral, melanoma; purple, ovarian cancer; gold, renal cancer; turquoise, prostate
cancer; pink, breast cancer.
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Reagents were obtained from the indicated suppliers: HBSS without
phenol red and trypsin-EDTA (0.25%), Invitrogen/Gibco; PBS, Mediatech; 4′,6-
diamidino-2-phenylindole dihydrochloride (DAPI) and DMSO, Sigma-Aldrich;
paraformaldehyde, Electron Microscopy Sciences; WGA, Alexa Fluor 488
conjugate, Invitrogen/Molecular Probes; and ProLong Gold Antifade Mount-
ant with DAPI, Life Technologies.
Human Cancer Cell Lines. Four cell lines from the NCI60 cell panel (44) rep-
resenting four distinct tumor types were used in this study: DU-145, prostate;
MDA-MB-231, breast; SK-MEL-28, melanoma; and OVCAR-3, ovarian. Cells
were grown in RPMI 1640 cell culture medium (Mediatech) containing 2 mM
L-glutamine, supplemented with 10% FBS (Omega Scientific), and main-
tained at 37 °C under 5% CO2 in a humidified incubator.
MTS Assay. Cells (DU-145, MDA-MB-231, SK-MEL-28, and OVCAR-3) were
seeded in 96-well microtiter plates (5 × 103 cells per well; 0.09 mL per well)
24 h before the addition of corroles. At the time of drug treatment, stock
solutions of 1–4 were diluted to 10-fold the desired final test concentrations
with RPMI medium 1640. Aliquots of 10 μL of these diluted solutions were
added to the appropriate microtiter wells containing 90 μL of medium,
resulting in the required final drug concentrations (eight concentrations per
compound, ranging from 0.3 to 600 μM). The final concentration of DMSO in
test culture was <1%. All cells were incubated in the dark throughout the
72-h exposure period and did not receive prolonged exposure to light.
Following 72 h of exposure at 37 °C, cell viability was determined using the
MTS assay (CellTiter 96 Aqueous One Cell Proliferation Assay; Promega)
according to the manufacturer’s instructions. Absorbances were measured
using a microplate reader (Synergy 4; Biotek Instruments) at 490 nm. Experi-
ments were performed in triplicate and each dose–response curve represents
the mean of three or more independent experiments. Spectrophotometric
data were analyzed by sigmoid dose–response, nonlinear regression analysis;
the IC50, Hill slope (γ), Emax values, and associated SE were calculated using
GraphPad Prism 6 (GraphPad Software).
Confocal Imaging of Intracellular Gallium Corroles. Confocal images were
obtained for DU-145, MDA-MB-231, SK-MEL-28, and OVCAR-3 cells exposed
to 3 μM 1, 2, 3, or 4 for 3 h at 37 °C, 5% CO2 in the dark using an upright
LSM510 2-Photon microscope (Carl Zeiss MicroImaging). Protocols for seed-
ing cells, immunolabeling, and confocal image acquisition were as previously
described (41).
Uptake of Gallium Corroles. The intracellular uptake of gallium corroles was
quantified using the ImageXpressultra laser point-scanning confocal micro-
scope (Molecular Devices). The fluorescence image acquisition settings were
as previously reported (41). Cells (DU-145, SK-MEL-28, MDA-MB-231, and
OVCAR-3) were seeded in 96-well dishes (8 × 103 cells per well in 0.1 mL) and
allowed to attach overnight. Compound 1, 2, 3, or 4 was added directly to
cell media at 30 μM final concentration or media only control, and incubated
for 0.25, 1, 3, or 24 h at 37 °C in the dark under a 5% CO2 atmosphere. Cells
were fixed and labeled in situ with WGA–Alexa Fluor 488 conjugate and
DAPI to allow for the identification of cell boundary and nucleus, re-
spectively. The quantification of blue (DAPI) fluorescence signals in each
sample yielded the total number of cells in that population. Corresponding
determination of red (corrole) fluorescence within each cell, corrected for
background fluorescence from untreated cells, provided the number of cells
containing corroles. For each corrole concentration at various time points,
fluorescence data were obtained for 1,000–22,000 individual cells. Data ac-
quisitions and analyses were performed as described (41). The percentage of
corrole-positive cells and the median fluorescence intensity (median RFU) for
each treatment were plotted in a three-axis graph using Microsoft Office
Excel 2007 (Microsoft Corporation).
NCI60 Anticancer Drug Screen. The aminocaproate-substituted corrole 3 was
submitted to NCI for cytotoxic screening at a single high dose (10−5 M) in a panel
of 60 human tumor cell lines (NCI60) (44, 57). Details of the cytotoxicity as-
sessment in the NCI anticancer drug screen have been described previously (58).
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Table 3. Cytotoxicity of 3 in NCI60 cell panel
Panel/cell line Growth inhibition, % Lethality, %
Leukemia
CCRF-CEM 91.1
HL-60(TB) 86.1
K-562 72.9
MOLT-4 86.0
RPMI-8226 70.2
SR 87.5
Non–small-cell lung cancer
A549/ATCC 82.7
EKVX 59.7
HOP-62 44.9
HOP-92 81.6
NCI-H226 61.1
NCI-H23 64.5
NCI-H322M 32.9
NCI-H460 94.2
NCI-H522 44.6
Colon cancer
COLO 205 51.7
HCC-2998 60.1
HCT-116 75.5
HCT-15 57.0
HT29 60.6
KM12 80.6
SW-620 75.9
CNS cancer
SF-268 65.8
SF-295 53.2
SF-539 85.3
SNB-75 30.7
U251 77.4
Melanoma
LOX IMVI 9.7
MALME-3M 50.4
M14 84.1
MDA-MB-435 90.8
SK-MEL-2 64.1
SK-MEL-28 12.1
SK-MEL-5 72.0
UACC-257 37.2
UACC-62 91.6
Ovarian cancer
IGROV1 55.7
OVCAR-3 75.9
OVCAR-4 59.9
OVCAR-5 53.1
OVCAR-8 67.3
NCI/ADR-RES 52.7
SK-OV-3 32.9
Renal cancer
A498 99.0
ACHN 73.2
CAKI-1 71.7
RXF 393 96.7
SN12C 78.8
TK-10 47.3
UO-31 64.7
Prostate cancer
PC-3 71.9
DU-145 64.7
Breast cancer
MCF7 63.1
MDA-MB-231/ATCC 72.5
HS 578T 81.2
BT-549 73.0
T-47D 45.9
MDA-MB-468 86.3
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